查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1611201

非類固醇消炎劑市場規模、佔有率、趨勢分析報告：按適應症、給藥途徑、分銷管道、地區和細分市場預測，2025-2030年

Non-steroidal Anti-inflammatory Drugs Market Size, Share & Trends Analysis Report By Disease Indication (Arthritis, Ophthalmic Diseases), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

非類固醇消炎劑市場成長及趨勢

Grand View Research, Inc.最新報告顯示，預計到2030年，全球非類固醇消炎劑市場規模將達到312.9億美元，2025年至2030年複合年成長率為5.66%。非類固醇消炎劑是主要用於緩解發炎和疼痛以及降低體溫的藥物。非類固醇消炎劑（NSAID）旨在緩解經痛、頭痛、發燒、關節炎、扭傷、拉傷和其他慢性疼痛等症狀，其普及率很高，預計將在預測期內推動市場發展。

由於全球目標疾病和慢性疼痛的盛行率上升以及這些疾病在老年人群中的高盛行率等因素，非類固醇消炎劑市場出現了成長機會。此外，對非處方非類固醇抗發炎藥的需求不斷增加，以及治療頭痛、偏頭痛和月經痛的非類固醇抗發炎藥的使用不斷增加，預計也將推動預測期內的成長。

此外，關節炎和其他疼痛相關疾病的日益普及也有望支持成長。例如，英國、法國和德國的骨關節炎盛行率高於其他歐洲國家。體力活動較多的人關節炎的盛行率較低，且預期盛行率會隨著年齡的成長而增加。因此，關節炎盛行率的上升預計也將促進預測期內的成長。

主要市場參與企業正在採取策略性舉措，例如地理擴張和採用非類固醇消炎劑組合藥物，以增加市場佔有率。例如，Alkem Labs 和 Dr. Reddy's Laboratories Ltd 正在美國銷售非類固醇消炎劑。此外，用於治療疼痛和其他發炎性疾病的非處方藥的核准增加預計也將推動預測期內的成長。因此，由於主要企業採取的各種策略，市場可能會促進成長。

不同地區的政府正在採取措施減輕偏頭痛、關節炎和其他疾病的負擔，以利於他們自己。例如，美國國立衛生研究院推出了 HEAL，以加速改善疼痛和發炎性疾病管理的研究工作。此外，以患者為中心的結果研究所已採取舉措引入非鴉片類藥物治療疼痛的選擇。預計這些措施將在預測期內促進成長。

非類固醇消炎劑市場報告亮點

  • 2024 年，由於關節炎在全球範圍內的高盛行率，關節炎細分市場將主導非類固醇抗發炎藥物市場。
  • 零售藥局領域佔最大佔有率，預計在預測期內將保持其主導地位。
  • 由於全部區域疼痛及相關疾病的高發病率、大量患者以及不斷增加的老年人口等因素，預計亞太地區在預測期內將以顯著的複合年成長率成長。
  • 由於關節炎的高發病率、主要市場參與企業的存在以及該地區研究活動的增加，北美將在 2024 年佔據市場主導地位。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章非類固醇消炎劑市場變數、趨勢、範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 非類固醇消炎劑市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章非類固醇消炎劑市場：按適應症預測及趨勢分析

  • 細分儀表板
  • 非類固醇消炎劑市場：適應疾病變異分析
  • 按適應症分類的非類固醇消炎劑市場前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 關節炎
  • 偏頭痛
  • 眼科疾病
  • 其他

第5章非類固醇消炎劑市場：依給藥途徑估算及趨勢分析

  • 細分儀表板
  • 非類固醇消炎劑市場：給藥途徑變異分析
  • 按給藥途徑分類的非類固醇消炎劑市場前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 口服
  • 局部的
  • 其他

第6章非類固醇消炎劑市場：依通路估算及趨勢分析

  • 細分儀表板
  • 非類固醇消炎劑市場：通路波動分析
  • 非類固醇消炎劑按分銷管道的市場前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章非類固醇消炎劑市場：區域、估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 市場參與企業分類
  • 主要市場參與企業的最新趨勢和影響分析
  • 2024 年企業市場佔有率分析
  • 主要企業簡介
    • Pfizer Inc.
    • Bayer AG
    • GSK plc
    • Dr. Reddy's Laboratories Ltd
    • Viatris Inc
    • Teva Pharmaceutical Industries Ltd.
    • Johnson And Johnson Services, Inc.
    • Merck &Co., Inc.
Product Code: GVR-4-68039-952-5

Non-steroidal Anti-inflammatory Drugs Market Growth & Trends:

The global non-steroidal anti-inflammatory drugs market size is estimated to reach USD 31.29 billion by 2030, registering a CAGR of 5.66% from 2025 to 2030, according to a new report by Grand View Research, Inc. Nonsteroidal anti-inflammatory drugs are drugs that are primarily used to relieve inflammation and pain, as well as to lower elevated body temperature. The high prescription rate of non-steroidal anti-inflammatory drugs (NSAIDs) for relief of symptoms of painful periods, headaches, fever, arthritis, sprains, strains, and other types of chronic pain is expected to drive the market during the forecast period.

The non-steroidal anti-inflammatory drugs market is expected to witness growth opportunities owing to factors such as the rising prevalence of targeted diseases and chronic pain across the globe, coupled with the high prevalence of these diseases in the geriatric population. Moreover, increasing demand for OTC NSAIDs and the rising adoption of NSAIDs for headaches, migraines, and menstrual pain are also expected to boost the growth during the forecast period.

Moreover, the increasing prevalence of arthritis and other pain-related disorders is also expected to support the growth. For instance, the prevalence of osteoarthritis is higher in the UK, France, and Germany compared to other countries in the Europe region. The prevalence of arthritis is seen to be lower in people who are often engaged in physical activities, and its prevalence rises with age. Thus, the rising prevalence of arthritis is also expected to cater to the growth during the forecast period.

Key market players are adopting strategic initiatives such as geographical expansion and the introduction of combination non-steroidal anti-inflammatory drugs to increase their market share across the globe. For instance, Alkem Labs and Dr. Reddy's Laboratories Ltd have launched their non-steroidal anti-inflammatory drugs in the U.S. Moreover, increasing approval of OTC drugs for pain management and other inflammatory diseases is expected to drive growth during the forecast period. Thus, owing to the various strategies adopted by key players, the market is likely to boost its growth.

Governments in various regions are undertaking favorable initiatives to reduce the burden of migraine, arthritis, and other diseases in their countries. For instance, the National Institutes of Health has initiated HEAL to accelerate research activities to improve the management of pain and inflammatory diseases. Moreover, the Patient-Centered Outcomes Research Institute has undertaken initiatives to introduce non-opioid treatment options for pain. Such initiatives are expected to increase growth during the forecast period.

Non-steroidal Anti-inflammatory Drugs Market Report Highlights:

  • In 2024, the arthritis segment dominated the NSAIDs market owing to the higher prevalence of arthritis across the globe
  • The retail pharmacy segment held the largest share and is anticipated to maintain its dominance during the forecast period
  • Asia Pacific region is expected to grow at a significant CAGR during the forecast period, owing to factors such as the high prevalence of pain and related disorders, the high pool of patients, and a rising geriatric population across the region
  • North America dominated the market in 2024, due to the higher prevalence of arthritis, the presence of leading market players, and increased research activities within the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease Indication
    • 1.2.2. Route of Administration
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional Scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Non-Steroidal Anti-Inflammatory Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Prevalence of Chronic Pain and Inflammatory Diseases
      • 3.2.1.2. Increase in geriatric population
      • 3.2.1.3. Awareness and Accessibility of OTC NSAIDs
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Side Effects
      • 3.2.2.2. Competition from Alternative Therapies
  • 3.3. Non-Steroidal Anti-Inflammatory Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Non-Steroidal Anti-Inflammatory Drugs Market: Disease Indication Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Non-Steroidal Anti-Inflammatory Drugs Market: Disease Indication Movement Analysis
  • 4.3. Non-Steroidal Anti-Inflammatory Drugs Market by Disease Indication (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Arthritis
    • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Migraine
    • 4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Ophthalmic Diseases
    • 4.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Non-Steroidal Anti-Inflammatory Drugs Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Non-Steroidal Anti-Inflammatory Drugs Market: Route of Administration Movement Analysis
  • 5.3. Non-Steroidal Anti-Inflammatory Drugs Market by Route of Administration Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Oral
    • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Topical
    • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Non-Steroidal Anti-Inflammatory Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Non-Steroidal Anti-Inflammatory Drugs Market: Distribution Channel Movement Analysis
  • 6.3. Non-Steroidal Anti-Inflammatory Drugs Market by Distribution Channel Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 To 2030 for the following
  • 6.5. Hospital Pharmacy
    • 6.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Retail Pharmacy
    • 6.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Online Pharmacy
    • 6.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Non-Steroidal Anti-Inflammatory Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Recent Developments & Impact Analysis by Key Market Participants
  • 8.3. Company Market Share Analysis, 2024
  • 8.4. Key Company Profiles
    • 8.4.1. Pfizer Inc.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Bayer AG
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. GSK plc
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Dr. Reddy's Laboratories Ltd
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Viatris Inc
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Teva Pharmaceutical Industries Ltd.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Johnson And Johnson Services, Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Merck & Co., Inc.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. North America NSAIDs Market, By Country, 2018 - 2030 (USD Million)
  • Table 4. North America NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 5. North America NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 6. North America NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 7. U.S. NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 8. U.S. NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 9. U.S. NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 10. Canada NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 11. Canada NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 12. Canada NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 13. Mexico NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 14. Mexico NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 15. Mexico NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 16. Europe NSAIDs Market, By Country, 2018 - 2030 (USD Million)
  • Table 17. Europe NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 18. Europe NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 19. Europe NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 20. UK NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 21. UK NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 22. UK NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 23. Germany NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 24. Germany NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 25. Germany NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 26. France NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 27. France NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 28. France NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 29. Spain NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 30. Spain NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 31. Spain NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 32. Italy NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 33. Italy NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 34. Italy NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 35. Denmark NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 36. Denmark NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 37. Denmark NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 38. Sweden NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 39. Sweden NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 40. Sweden NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 41. Norway NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 42. Norway NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 43. Norway NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 44. Asia Pacific NSAIDs Market, By Country, 2018 - 2030 (USD Million)
  • Table 45. Asia Pacific NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 46. Asia Pacific NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 47. Asia Pacific NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 48. Japan NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 49. Japan NSAIDs Market, By Route of Administration 2018 - 2030 (USD Million)
  • Table 50. Japan NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 51. China NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 52. China NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 53. China NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 54. India NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 55. India NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 56. India NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 57. South Korea NSAIDs Market, By disease indication 2018 - 2030 (USD Million)
  • Table 58. South Korea NSAIDs Market, By route of administration 2018 - 2030 (USD Million)
  • Table 59. South Korea NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 60. Australia NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 61. Australia NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 62. Australia NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 63. Thailand NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 64. Thailand NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 65. Thailand NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 66. Latin America NSAIDs Market, By Country, 2018 - 2030 (USD Million)
  • Table 67. Latin America NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 68. Latin America NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 69. Latin America NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 70. Brazil NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 71. Brazil NSAIDs Market, By Route of Administration 2018 - 2030 (USD Million)
  • Table 72. Brazil NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 73. Argentina NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 74. Argentina NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 75. Argentina NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 76. Middle East & Africa NSAIDs Market, By Country, 2018 - 2030 (USD Million)
  • Table 77. Middle East & Africa NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 78. Middle East & Africa NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 79. Middle East & Africa NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 80. South Africa NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 81. South Africa NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 82. South Africa NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 83. Saudi Arabia NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 84. Saudi Arabia NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 85. Saudi Arabia NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 86. UAE NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 87. UAE NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 88. UAE NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)
  • Table 89. Kuwait NSAIDs Market, By disease indication, 2018 - 2030 (USD Million)
  • Table 90. Kuwait NSAIDs Market, By route of administration, 2018 - 2030 (USD Million)
  • Table 91. Kuwait NSAIDs Market, By distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research approaches
  • Fig. 2 Value chain-based sizing & forecasting
  • Fig. 3 Market formulation & validation
  • Fig. 4 non-steroidal anti-inflammatory drugs market segmentation
  • Fig. 5 Market driver analysis (current & future impact)
  • Fig. 6 Market restraint analysis (current & future impact)
  • Fig. 7 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 8 Porter's five forces analysis
  • Fig. 9 NSAIDs market: Disease indication outlook and key takeaways
  • Fig. 10 NSAIDs market: Disease indication movement analysis
  • Fig. 11 Arthritis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 12 Migraine market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 13 Ophthalmic diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 NSAIDs market: Route of administration outlook and key takeaways
  • Fig. 16 NSAIDs market: Route of administration movement analysis
  • Fig. 17 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Topical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 NSAIDs market: Distribution channel outlook and key takeaways
  • Fig. 21 NSAIDs market: Distribution channel movement analysis
  • Fig. 22 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 North America non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 US non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Canada non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Mexico non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Europe non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 UK non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Germany non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 France non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Italy non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Spain non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Denmark non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Sweden non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Norway non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Asia Pacific non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Japan non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 China non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 India non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Australia non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Thailand non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 South Korea non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Latin America non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Brazil non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Argentina non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 MEA non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 South Africa non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Saudi Arabia non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 UAE non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Kuwait non-steroidal anti-inflammatory drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 List of key emerging company's/disruptors/innovators